PubMed Health⌕ Search

Biomedical subjects

J P Gylding-Sabroe

Publications and source records attributed to J P Gylding-Sabroe.

12 recordsLinked to original sources
PubMed1985

Kinetics of citalopram in elderly patients.

The kinetics of the antidepressant drug citalopram, a specific 5-HT uptake inhibitor, has been investigated in 11 elderly patients (age 73-90) and compared to previous data from younger patients and volunteers. The recorded steady state citalopram levels of 140-545 nM after a once-daily 20-mg dose were up to four times higher than expected from data in younger patients and volunteers. The biological half-life (1.5-3.75 days) and estimated systemic clearance (0.08-0.3 1/min) also differed from data in younger individuals (1.5 days and 0.4 1/min, respectively). Clearance values generally decreased with increasing age. Drug/metabolite ratios were higher in patients with the longest half-lives and lowest citalopram clearance, indicating reduced metabolic activity. No reduction in renal clearance was indicated by urine data, obtained for two of the patients. The study suggests that daily doses of 5-20 mg give approximately the same steady state plasma levels in elderly patients as doses of 40 mg in younger, and that this is due to reduced rates of metabolism in the elderly.

Aged↗
PubMed1983

Bioavailability of naproxen tablets and suppositories in steady state.

Serum profiles were obtained from patients with rheumatoid arthritis after treatment with naproxen tablets and suppositories for 10 days to assure steady state conditions. The serum concentrations immediately before dose intake correlated well with the area under the concentration curve (AUC) when 250 mg naproxen tablets were taken 12-hourly (r = 0.85) and when 500 mg naproxen was given as tablets or as suppositories once daily in the evening (r = 0.83). These fixed times for blood samplings should be used in clinical trials with naproxen. Naproxen was measured by mass fragmentography. The mean steady state concentration and the mean half-life, calculated from the 12-hourly dosage schedule, were 45.0 +/- 1.7 mg/l and 15.2 +/- 1.4 hours, respectively. Doubling the dose from 250 mg to 500 mg b.i.d. increased the AUC by 30%. Average serum profiles for tablets and suppositories were very similar and gave a relative bioavailability of suppositories compared to tablets of 103% +/- 4%, suggesting comparable efficacy of the two administration forms.

Adult↗
PubMed1978

Possible causes of treatment failure with the NSAID.

The clinical efficacy of non-steroidal anti-inflammatory drugs (NSAID) is often disappointing in spite of their well-known antiphlogistic actions. The reasons for this failure are probably due to irregular intake by patients on long-term treatment with such agents. These considerations inevitably point to the necessity of concomitant determination of the plasma levels of all NSAID tested, and the need to perform clinical trials in an appropriate setting in which such determinations can be conveniently carried out.

Anti-Inflammatory Agents↗